Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

Autor: Mathurin, P., Gournay, J., Nguyen-Khac, E., De Ledinghen, V., Larrey, D., Tran, A., Bourliere, M., Maynard-Muet, M., Asselah, T., Henrion, J., Nevens, F., Cassiman, D., Geerts, A., Moreno, C., Beuers, U.H., Galle, P.R., Spengler, U., Bugianesi, E., Craxi, A., Angelico, M., Fargion, S., Voiculescu, M., Gheorghe, L., Preotescu, L., Caballeria, J., Andrade, R.J., Crespo, J., Callera, J.L., Ala, A., Aithal, G., Abouda, G., Luketic, V., Huang, M.A., Gordon, S., Pockros, P., Poordad, F., Shores, N., Moehlen, M.W., Bambha, K., Clark, V., Satapathy, S., Parekh, S., Reddy, R.K., Sheikh, M.Y., Szabo, G., Vierling, J., Foster, T., Umpierrez, G., Chang, C., Box, T., Gallegos-Orozco, J., Ratziu, Vlad, Harrison, Stephen A., Francque, Sven, Bedossa, Pierre, Lehert, Philippe, Serfaty, Lawrence, Romero-Gomez, Manuel, Boursier, Jérôme, Abdelmalek, Manal, Caldwell, Steve, Drenth, Joost, Anstee, Quentin M., Hum, Dean, Hanf, Remy, Roudot, Alice, Megnien, Sophie, Staels, Bart, Sanyal, Arun

Publikováno v: In Gastroenterology May 2016 150(5):1147-1159

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis

Autor: Pageaux, G. (Georges-Philippe), Nzinga, C. (Clovis Lusivika), Ganne, N. (Nathalie), Samuel, D. (Didier), Dorival, C. (Céline), Zoulim, F. (Fabien), Cagnot, C. (Carole), Decaens, T. (Thomas), Thabut, D. (Dominique), Asselah, T. (Tarik), Mathurin, P. (Philippe), Habersetzer, F. (Francois), Bronowicki, J. (Jean-Pierre), Guyader, D. (Dominique), Rosa, I. (Isabelle), Leroy, V. (Vincent), Chazouilleres, O. (Olivier), de Ledinghen, V. (Victor), Bourliere, M. (Marc), Causse, X. (Xavier), Cales, P. (Paul), Metivier, S. (Sophie), Loustaud-Ratti, V. (Véronique), Riachi, G. (Ghassan), Alric, L. (Laurent), Gelu-Simeon, M. (Moana), Minello, A. (Anne), Gournay, J. (Jérôme), Geist, C. (Claire), Tran, A. (Albert), Abergel, A. (Armand), Portal, I. (Isabelle), d'Alteroche, L. (Louis), Raffi, F. (François), Fontaine, H. (Hélène), Carrat, F. (Fabrice), Pol, S. (Stanislas), Baumert, Thomas F., Doffoel, M. (Michel), Mutter, C. (Catherine), Simo-Noumbissie, P. (Pauline), Razi, E. (Esma)

Publikováno v: BMC Infectious Diseases
BMC Infectious Diseases, BioMed Central, 2022, 22 (1), pp.94. ⟨10.1186/s12879-022-07076-0⟩
BMC Infectious Diseases, 2022, 22 (1), pp.94. ⟨10.1186/s12879-022-07076-0⟩
BMC Infectious Diseases, Vol 22, Iss 1, Pp 1-12 (2022)

Background In HCV-infected patients with advanced liver disease, the direct antiviral agents-associated clinical benefits remain debated. We compared the clinical outcome of patients with a previous history of decompensated cirrhosis following treatm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a64389812730cdee1f356f6f46786008
https://hal.archives-ouvertes.fr/hal-03555553/document

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.